prion-like-spreading

Prion-Like Spreading

Introduction

Prion Like Spreading is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[@jucker2013] [@fitzpatrick2017]

Overview

Prion-like spreading refers to the template-directed, self-propagating transmission of misfolded protein aggregates between cells in the nervous system. In this mechanism, pathological protein conformers (seeds) are released from one cell, taken up by a neighboring cell, and recruit endogenous normal protein to adopt the same misfolded conformation — propagating pathology through neural circuits in a manner analogous to infectious prions. This concept has fundamentally reshaped understanding of neurodegenerative disease progression, explaining why pathology in Alzheimer's Disease], Parkinson's Disease], ALS, and other conditions follows stereotypical anatomical patterns ([Jucker & Walker, 2013](https://doi.org/10.1038/nature12481)). [@li2008]
[@fitzpatrick2017] [@schweighauser2020]

Prion-Like Spreading

Introduction

Prion Like Spreading is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[@jucker2013] [@fitzpatrick2017]

Overview

Prion-like spreading refers to the template-directed, self-propagating transmission of misfolded protein aggregates between cells in the nervous system. In this mechanism, pathological protein conformers (seeds) are released from one cell, taken up by a neighboring cell, and recruit endogenous normal protein to adopt the same misfolded conformation — propagating pathology through neural circuits in a manner analogous to infectious prions. This concept has fundamentally reshaped understanding of neurodegenerative disease progression, explaining why pathology in Alzheimer's Disease], Parkinson's Disease], ALS, and other conditions follows stereotypical anatomical patterns ([Jucker & Walker, 2013](https://doi.org/10.1038/nature12481)). [@li2008]
[@fitzpatrick2017] [@schweighauser2020]

Critically, the term "prion-like" distinguishes these mechanisms from true prion diseases: while the proteins share the capacity for templated misfolding and cell-to-cell spread, the neurodegenerative disease-associated aggregates are not naturally transmissible between individuals under normal circumstances (unlike PrPSc in Creutzfeldt-Jakob Disease or BSE). However, the molecular principles — seeded nucleation, conformational strains, and circuit-based propagation — are remarkably conserved. [@yang2024]
[@li2008] [@braak2003]

Molecular Mechanisms

Seeded Nucleation

The core mechanism of prion-like propagation follows a nucleation-polymerization model: [@holmes2013]

The rate-limiting step is primary nucleation (initial seed formation), which explains why sporadic diseases have long presymptomatic phases but then progress relatively rapidly once seeding reaches a threshold. [@soto2018]

Cell-to-Cell Transmission

Multiple pathways mediate the transfer of pathological seeds between cells: [@shahnawaz2020]

| Pathway | Mechanism | Evidence | Key [Proteins/proteins) | [@meisl2025]
|---------|-----------|----------|-------------|
| Synaptic transmission | Release at presynaptic terminal; uptake by postsynaptic neuron | Tau](/proteins/amyloid-beta) |
| Exosome-mediated | Seeds packaged in extracellular vesicles (30-150 nm) | Exosomal tau] and α-syn from patient CSF can seed aggregation | Tau, α-syn, PrP |
| Tunneling nanotubes | Direct cytoplasmic bridges between cells | Observed for tau, α-syn, and PrP transfer | Tau, α-syn, PrP |
| Bulk exocytosis/endocytosis | Non-vesicular release; uptake via macropinocytosis or receptor-mediated endocytosis | TDP-43], tau fibrils taken up by neurons] | All prion-like proteins |
| Heparan sulfate proteoglycans | Cell surface receptors for aggregate uptake | HSPG-dependent uptake of tau, α-syn fibrils | Tau, α-syn |

Conformational Strains

A crucial discovery: the same protein can adopt multiple distinct misfolded conformations (strains), each encoding different disease properties:

• Different strains have distinct biochemical signatures (protease resistance, seeding efficiency)
• Strains faithfully propagate their conformation to newly recruited monomers
• Different strains may underlie clinical heterogeneity within the same disease
• Cryo-EM has revealed the structural basis of strains at atomic resolution

Proteins with Prion-Like Behavior

Tau

Tau propagation is the best-characterized prion-like mechanism in AD:

• Braak staging: Tau pathology progresses stereotypically from entorhinal [cortex] → hippocampus] → association cortex → primary cortex, following neural connectivity
• Experimental evidence: Injection of AD-brain-derived tau into mouse hippocampus induces spreading pathology along connected circuits ([de Calignon et al., 2012](https://doi.org/10.1016/j.neuron.2011.11.033))
• Strain diversity: Cryo-EM structures reveal distinct tau folds in AD (paired helical filaments, straight filaments), Pick's disease, CBD, PSP, and CTE — each with a unique fibril structure ([Fitzpatrick et al., 2017](https://doi.org/10.1038/nature23002))
• Seeding activity: Tau seeds detectable in AD brain and CSF using seed amplification assays (SAA/RT-QuIC)

alpha-synuclein

alpha-synuclein spreading underlies Parkinson's Disease progression:

• Braak hypothesis: α-Synuclein Lewy pathology begins in the olfactory bulb and dorsal motor nucleus of the vagus, ascending through the brainstem to substantia nigra and cortex
• Host-to-graft transmission: Embryonic dopamine neuron grafts develop Lewy bodies 10-15 years after transplantation into PD patients — definitive evidence of host-to-graft spread
• Strain diversity: Cryo-EM reveals distinct α-synuclein folds — the "Lewy fold" (PD/DLB) versus the "MSA fold" (Multiple System Atrophy) — explaining clinical differences between synucleinopathies
• Diagnostic SAA: α-Synuclein seed amplification assay in CSF has >90% sensitivity and specificity for PD diagnosis; can distinguish PD from MSA strains

Amyloid-Beta

amyloid-beta exhibits prion-like properties, though its spreading pattern is less circuit-dependent:

• Intracerebral injection of AD brain homogenate induces Aβ pathology in APP] transgenic mice
• Iatrogenic transmission: Aβ pathology found in patients who received cadaveric growth hormone or dura mater grafts decades earlier
• Aβ seeds are resistant to formaldehyde fixation and autoclaving
• Different Aβ strains produce distinct plaque morphologies (diffuse vs. cored)

TDP-43

TDP-43 aggregation in ALS and Frontotemporal Dementia (FTD) shows prion-like features:

• TDP-43 seeds from FTLD subtypes produce distinct aggregation patterns in cell culture
• Cryo-EM reveals polymorphic TDP-43 fibril structures sharing an "amyloid key" motif (2024)
• Different TDP-43 strains show different susceptibility to protease digestion and distinct spreading patterns in vivo
• TDP-43 pathology can spread from the spinal cord to brain in ALS models

Huntingtin

Mutant huntingtin/proteins/huntingtin)] (mHTT) with expanded polyglutamine tracts can propagate:

• mHTT aggregates can be taken up by neurons and seed endogenous mHTT aggregation
• Spreading is observed in cell culture and Drosophila models
• The polyglutamine expansion itself confers seeding capacity

Cryo-EM Structures of Disease-Associated Fibrils

Recent cryo-EM advances (2017-2025) have revolutionized understanding of protein strains:

| Protein | Disease | Fold Name | Key Structural Feature |
|---------|---------|-----------|----------------------|
| Tau | AD | PHF/SF | C-shaped fold; R3-R4 repeat region |
| Tau | Pick's disease | Pick fold | Elongated, J-shaped |
| Tau | CBD | CBD fold | Four-layered; 3R+4R tau |
| Tau | PSP | PSP fold | Distinct from CBD despite clinical overlap |
| Tau | CTE | CTE fold | Unique hydrophobic cavity |
| α-Synuclein | PD/DLB | Lewy fold | Greek key motif |
| α-Synuclein | MSA | MSA fold | Two distinct protofilament interfaces |
| TDP-43 | ALS/FTLD | Amyloid key | Dagger-shaped fold with polymorphic protofilaments |
| Aβ | AD (type I/II) | Multiple folds | S-shaped; distinct in sporadic vs. familial AD |

These structures demonstrate that each disease has a characteristic fibril fold, potentially serving as the molecular basis for disease-specific clinical and pathological features.

Seed Amplification Assays (SAA)

Seed amplification assays exploit the prion-like seeding properties of pathological proteins for diagnosis:

• Principle: Patient biofluid (CSF, blood) containing minute amounts of seeds is incubated with recombinant substrate protein. Seeds template conversion, producing detectable amyloid signal (thioflavin T fluorescence)
• α-Synuclein SAA: FDA-recognized biomarker for PD; >92% sensitivity, >95% specificity from CSF; can distinguish PD from MSA strains based on kinetic parameters
• Tau SAA/RT-QuIC: Detecting tau seeds in AD CSF; 3R vs. 4R tau discrimination for Pick's vs. CBD/PSP
• TDP-43 SAA: Earlier-stage development; detecting TDP-43 seeds in ALS/FTD biospecimens
• Blood-based SAA: Active development area for non-invasive screening (2024-2025)

Therapeutic Implications

Anti-Seeding Immunotherapy

Antibodies designed to intercept seeds during cell-to-cell transfer:

• Anti-tau antibodies: Semorinemab, zagotenemab, bepranemab target extracellular tau species; clinical trials/clinical-trials) showed limited efficacy, suggesting intracellular propagation may be more important
• Anti-α-synuclein antibodies: [Prasinezumab showed modest slowing of motor progression in Phase 2 PD trial
• Anti-Aβ immunotherapy: lecanemab/therapeutics/lecanemab)] and donanemab target aggregated Aβ species that include seeds

Blocking Cellular Uptake

• HSPG antagonists (heparin mimetics) to block aggregate endocytosis
• Receptor decoys to intercept extracellular seeds
• Exosome release inhibitors (GW4869) to reduce vesicular seed transfer

Preventing Templated Conversion

• Small molecules that stabilize native protein conformation
• Molecular chaperone enhancers
• Antisense oligonucleotides (ASOs) to reduce the pool of convertible substrate protein (e.g., tau ASOs, α-synuclein ASOs in clinical trials)

Enhancing Seed Degradation

• Enhancing autophagy to degrade intracellular seeds
• Activating microglia
• Boosting proteasomal degradation of misfolded monomers

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
• [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data

Background

The study of Prion Like Spreading has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: [Prion-Like Spreading expression search](https://human.brain-map.org/microarray/search/show?search_term=Prion-Like+Spreading)
• Allen Mouse Brain Atlas: [Prion-Like Spreading search](https://mouse.brain-map.org/search/index.html?query=Prion-Like+Spreading)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Prion-Like Spreading developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Prion-Like+Spreading)
• [Alzheimer's Disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease)
• [Amyloid-Beta Aggregation](/proteins/amyloid-beta)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)](/genes/ar)
• [ALS](/diseases/als)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Microglia](/cell-types/microglia)
• [neuroinflammation](/mechanisms/neuroinflammation)
• [Autophagy](/mechanisms/autophagy)
• [Proteostasis Failure](/mechanisms/als-rna-metabolism-and-proteostasis-failure)

References